BRANFORD, Conn. / Sep 06, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 9-11, 2024. Company management will also be participating in one-on-one meetings during the conference. The on-demand... Read More

BRANFORD, Conn. / Aug 28, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The study is designed to enroll approximately 12 adult patients with twice-daily treatment for 14 days, with primary endpoints focusing on safety and tolerability,... Read More

New investigational new drug (IND) application cleared to proceed by the US FDA for a Phase 1/2 clinical study of ATR-04 for moderate to severe EGFR inhibitor (“EGFRi”) associated dermal toxicity. There are an estimated 150,000 patients with EGFRi-associated skin rash in the US, representing a >$1 billion global market size. Preclinical data show ATR-04 reduces IL-36γ and Staphylococcus aureus , key drivers of... Read More

BRANFORD, Conn. / Aug 20, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The patient is scheduled to initiate treatment by the end of the month. The study is designed to enroll approximately 12 adult patients with twice-daily... Read More

BRANFORD, Conn. / Aug 12, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide... Read More

BRANFORD, Conn. / Jul 25, 2024 / Business Wire / Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION PUBLIC OFFERING Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its... Read More

BRANFORD, Conn. / Jul 25, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share. Total gross proceeds from the offering, before deducting... Read More

BRANFORD, Conn. / Jul 23, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of a public offering of an aggregate of 6,665,000 shares of its common stock, and Class A warrants to purchase up to 13,330,000 shares of common stock, at a combined public offering price of... Read More

Newly issued U.S. patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of atopic dermatitis. Issuance date was July 16, 2024 Newly allowed patents in the U.S. and China protect the composition of a filaggrin-secreting strain of Staphylococcus epidermidis Newly allowed Canada patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for a number of skin diseases,... Read More

Common Stock Will Begin Trading on a Split-Adjusted Basis on July 1, 2024 BRANFORD, Conn. / Jun 27, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. The... Read More

BRANFORD, Conn. / May 31, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California. The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at... Read More

ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000 patients in the US Reduces methicillin-resistant S. aureus by 99% on ex vivo pig skin Reduces IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin Increases human beta defensin 18-fold vs.... Read More

ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndrome Topical application of ATR-12 to ex vivo human skin results in superior LEKTI delivery compared to topical LEKTI application ATR-12 reduces IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome Safe and well tolerated in minipigs BRANFORD, Conn. / May 10, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a... Read More

BRANFORD, Conn. / May 09, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update. Q1 2024 and Recent Business Highlights Advanced ATR-12's Phase 1b trial, activating sites, advancing central IRB approval,... Read More

Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 related to ATR-12, Azitra’s candidate for Netherton syndrome Topical application of ATR-12 to ex vivo human skin demonstrates the potential for superior LEKTI delivery compared to topical LEKTI application Preclinical data suggests ATR-12 can significantly reduce IL-36g, a pro-inflammatory cytokine... Read More

ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 SID (Society of Investigative Dermatology) Dallas, TX, May 15-18, 2024 ASCO (American Society of Clinical Oncology) Chicago, IL, May 31 – June 4, 2024 BRANFORD, Conn. / Apr 18, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,... Read More

BRANFORD, Conn. / Mar 15, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update. FY 2023 and Recent Business Highlights Completed an initial public offering, raising $7.5 million in gross proceeds.... Read More

BRANFORD, Conn. / Feb 16, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share. Total gross proceeds from the offering, before deducting... Read More

BRANFORD, Conn. / Feb 13, 2024 / Business Wire / Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of an underwritten public offering of 16,667,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.30 per share for gross proceeds of... Read More

Newly granted patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of ichthyosis vulgaris Ichthyosis vulgaris is a high unmet need with no FDA-approved treatment option and affects approximately 1.3 million people in the United States Broadens Azitra’s foundational intellectual property (IP) for its platform using metagenomics and engineered skin bacteria for precision dermatology... Read More

BRANFORD, Conn. / Jan 03, 2024 / Business Wire / Azitra, Inc . (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the Dermatology Summit 2024 , on Sunday, January 7, 2024 at 12:55pm PT and Biotech Showcase 2024 , Monday, January 8, 2024 at 3:30pm PT, alongside the J.P. Morgan 42nd Annual... Read More

BRANFORD, Conn. / Nov 14, 2023 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the third quarter ended September 30, 2023. Q3 and Recent Business Highlights Advanced its pipeline programs including ATR-12 (Netherton syndrome), ATR-04 (EGFRi-associated rash) and its Joint... Read More

BRANFORD, Conn. / Oct 16, 2023 / Business Wire / Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today that management will present at the ThinkEquity Conference in New York City on October 19 at 3:00pm ET. The presentation will be streamed live and available for replay at: https://wsw.com/webcast/tep24/aztr/1700335... Read More

BRANFORD, Conn. , Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today that Travis Whitfill , COO, will present an overview of the Company at the H.C. Wainwright 25th Annual Global Investment Conference, being held from September 11-13, 2023 . Company management will also be... Read More

BRANFORD, Conn. , Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the second quarter ended June 30, 2023 . Francisco Salva , Chief Executive Officer of Azitra, commented, "We are extremely pleased with the exciting recent progress at Azitra, and we are... Read More

BRANFORD, Conn. , July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer . "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth... Read More

BRANFORD, Conn. , July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical... Read More